Ever-improving data analytics driving better patient outcomes

27 January 2022
data_2022_large_shutterstock

Steve Kent, chairman at Pharmaspectra, a data business with a focus on medical affairs, provides an Expert View on the increasing impact of data in medicine.

The amount of science that is being conducted has gone up hugely in the last 10 years as well as the understanding and identification of the people who are relevant to a particular compound or therapy because medicine is becoming ever more specialized.

"A great opportunity for the outsourced pharma services industry"When I started my career in the early 1980s, there were around a dozen different known cancers; now there are more than 100. This is just one example of mankind’s greater medical knowledge and the increased level of specialization of our medical practitioners that comes with it. Our knowledge will continue to grow as the increasing amount of incoming data is harnessed by machine learning and other techniques.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical